Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat lymphoma: experimental drug shows promise Results expected Dec 2026 (estimated)
- Can common drugs change how a new cancer medicine works? Results expected Dec 2026 (estimated)
- Can a new experimental pill be safely given to people? Results expected Jul 2027 (estimated)
- New pill could help control blood disorder when standard drugs fail Results expected Jul 2027 (estimated)
-
New pill shows promise for rare blood cancer in early trial
Disease control CompletedThis early-phase trial tested a new drug called flonoltinib maleate in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow cancers. The main goals were to check safety, find the right dose, and see how the body processes the drug. Researchers hope this drug…
Phase 1/2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Healthy men needed to track Drug's path out of the body
Knowledge-focused CompletedThis early-stage study looks at how a drug called Flonoltinib maleate (being developed for a bone marrow condition) is processed and removed from the body. Six healthy adult men will take a single dose, and researchers will measure the drug and its breakdown products in blood, ur…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New JAK3 blocker ZL-82 passes first safety check in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested a new experimental drug, ZL-82, in 41 healthy adults to see if it is safe and how the body processes it. The drug targets a protein involved in immune signaling. Researchers also checked whether ZL-82 affects the heart's electrical activity. The resu…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Meal timing may change how this drug works
Knowledge-focused CompletedThis completed Phase 1 trial studied how taking flonoltinib maleate tablets with or without food changes the drug's levels in the blood. Twenty-four healthy adults aged 18 to 45 took a single 100 mg dose under both fed and fasting conditions. The goal was to understand food's imp…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New drug flonoltinib maleate tested for safety in healthy people
Knowledge-focused CompletedThis early-phase trial tested the safety and how the body processes flonoltinib maleate tablets in 40 healthy adults in China. Participants received a single oral dose of the drug or a placebo, with doses increasing across groups. The study focused on side effects and drug levels…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC